The combination of the novel GLS inhibitor CB839 with the EGFR monoclonal antibody Cetuximab showed efficacy in Cetuximab-sensitive and -resistant CRC cell models, indicating that patients with refractory metastatic CRC might benefit from this combination therapy targeting both the “fuel” and signaling components required for tumor survival [267]. This evidence concerns the gene EGFR and colorectal carcinoma.